BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 18823071)

  • 1. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
    Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
    Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
    Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
    Boos J; Werber G; Ahlke E; Schulze-Westhoff P; Nowak-Göttl U; Würthwein G; Verspohl EJ; Ritter J; Jürgens H
    Eur J Cancer; 1996 Aug; 32A(9):1544-50. PubMed ID: 8911116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy.
    Ylikangas P; Mononen I
    Anal Biochem; 2000 Apr; 280(1):42-5. PubMed ID: 10805519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
    Domenech C; Thomas X; Chabaud S; Baruchel A; Gueyffier F; Mazingue F; Auvrignon A; Corm S; Dombret H; Chevallier P; Galambrun C; Huguet F; Legrand F; Mechinaud F; Vey N; Philip I; Liens D; Godfrin Y; Rigal D; Bertrand Y
    Br J Haematol; 2011 Apr; 153(1):58-65. PubMed ID: 21332712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
    Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of a Precolumn OPA Derivatization HPLC Assay for Monitoring of l-Asparagine Depletion in Serum during l-Asparaginase Therapy.
    Zhang M; Zhang Y; Ren S; Zhang Z; Wang Y; Song R
    J Chromatogr Sci; 2018 Oct; 56(9):794-801. PubMed ID: 29878070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of L-asparaginase activity and biochemical parameters evaluation in children with acute lymphoblastic leukemia].
    Pawińska K; Balwierz W; Sztefko K; Czogała M
    Przegl Lek; 2006; 63(1):44-6. PubMed ID: 16892900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase].
    Wu ZL; Chen FX; Ye TZ; Lai YH; Cui YQ; Zou YW; Lu CY; Lan SL; Zhong GY; Guan JM; Wei FG; Zhang H
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):14-6. PubMed ID: 16732932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
    O'Driscoll KF; Korus RA; Ohnuma T; Walczack IM
    J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of L-asparagine in biological samples in the presence of L-asparaginase.
    Gentili D; Zucchetti M; Conter V; Masera G; D'Incalci M
    J Chromatogr B Biomed Appl; 1994 Jul; 657(1):47-52. PubMed ID: 7952083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
    Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
    Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Automated kinetic assay of plasmatic L-asparaginase activity undergoing therapy for acute lymphoblastic leukemia].
    Orsonneau JL; Brassart EA; Lecame M; Thomare P; Delaroche O; Dudouet D
    Ann Biol Clin (Paris); 2004; 62(5):568-72. PubMed ID: 15355807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin-Frankfurt-Münster-based induction therapy for childhood acute lymphoblastic leukemia.
    Steiner M; Hochreiter D; Kasper DC; Kornmüller R; Pichler H; Haas OA; Pötschger U; Hutter C; Dworzak MN; Mann G; Attarbaschi A
    Leuk Lymphoma; 2012 Sep; 53(9):1682-7. PubMed ID: 22356135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor.
    Asselin BL; Lorenson MY; Whitin JC; Coppola DJ; Kende AS; Blakley RL; Cohen HJ
    Cancer Res; 1991 Dec; 51(24):6568-73. PubMed ID: 1742729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monolith and coating enzymatic microreactors of L-asparaginase: kinetics study by MCE-LIF for potential application in acute lymphoblastic leukemia (ALL) treatment.
    Qiao J; Qi L; Mu X; Chen Y
    Analyst; 2011 May; 136(10):2077-83. PubMed ID: 21461410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.